$CHRS
Coherus BioSciences, Inc.

2024 Q3 Form 10-Q Financial Statement

#000155837024011629 Filed on August 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $70.77M $64.98M
YoY Change -5.09% 10.67%
Cost Of Revenue $20.74M $28.37M
YoY Change -36.58% 14.17%
Gross Profit $50.03M $36.61M
YoY Change 19.51% 8.1%
Gross Profit Margin 70.69% 56.34%
Selling, General & Admin $34.74M $35.17M
YoY Change -27.95% -22.1%
% of Gross Profit 69.44% 96.05%
Research & Development $21.68M $21.96M
YoY Change -15.48% -5.64%
% of Gross Profit 43.32% 59.97%
Depreciation & Amortization $400.0K $500.0K
YoY Change -50.0% -37.5%
% of Gross Profit 0.8% 1.37%
Operating Expenses $56.42M $57.12M
YoY Change -23.62% -16.5%
Operating Profit -$6.387M -$20.51M
YoY Change -80.04% -40.63%
Interest Expense $5.362M $5.334M
YoY Change -47.78% -46.35%
% of Operating Profit
Other Income/Expense, Net $2.084M $1.467M
YoY Change -7.5% -9.28%
Pretax Income -$10.75M -$12.92M
YoY Change -73.14% -69.86%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$10.75M -$12.92M
YoY Change -72.88% -69.86%
Net Earnings / Revenue -15.19% -19.88%
Basic Earnings Per Share -$0.09 -$0.11
Diluted Earnings Per Share -$0.09 -$0.11
COMMON SHARES
Basic Shares Outstanding 115.2M 114.7M
Diluted Shares Outstanding 115.2M 114.8M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $97.69M $159.2M
YoY Change -25.48% 10.04%
Cash & Equivalents $97.69M $159.2M
Short-Term Investments $0.00
Other Short-Term Assets $24.89M $22.96M
YoY Change -17.02% -35.28%
Inventory $47.64M $62.16M
Prepaid Expenses
Receivables $167.6M $175.3M
Other Receivables $31.24M $138.3M
Total Short-Term Assets $369.0M $557.9M
YoY Change -16.95% 44.74%
LONG-TERM ASSETS
Property, Plant & Equipment $2.911M $3.334M
YoY Change -52.03% -51.88%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $7.377M $8.256M
YoY Change -5.7% 9.74%
Total Long-Term Assets $136.0M $116.9M
YoY Change -2.47% 39.02%
TOTAL ASSETS
Total Short-Term Assets $369.0M $557.9M
Total Long-Term Assets $136.0M $116.9M
Total Assets $505.0M $674.9M
YoY Change -13.5% 43.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $21.89M $76.82M
YoY Change -40.98% 162.37%
Accrued Expenses $60.97M $61.04M
YoY Change -9.16% 45.99%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $295.6M $463.0M
YoY Change 23.33% 173.26%
LONG-TERM LIABILITIES
Long-Term Debt $264.5M $264.1M
YoY Change -44.05% -44.07%
Other Long-Term Liabilities $29.16M $27.70M
YoY Change 730.09% 27053.92%
Total Long-Term Liabilities $29.16M $27.70M
YoY Change 730.09% 27053.92%
TOTAL LIABILITIES
Total Short-Term Liabilities $295.6M $463.0M
Total Long-Term Liabilities $29.16M $27.70M
Total Liabilities $593.0M $759.0M
YoY Change -17.34% 17.79%
SHAREHOLDERS EQUITY
Retained Earnings -$1.500B -$1.490B
YoY Change 0.03% 2.01%
Common Stock $12.00K $12.00K
YoY Change 9.09% 33.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$87.97M -$84.11M
YoY Change
Total Liabilities & Shareholders Equity $505.0M $674.9M
YoY Change -13.5% 43.71%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$10.75M -$12.92M
YoY Change -72.88% -69.86%
Depreciation, Depletion And Amortization $400.0K $500.0K
YoY Change -50.0% -37.5%
Cash From Operating Activities -$62.02M $59.73M
YoY Change 14.21% -253.5%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $444.0K $27.66M
YoY Change -99.12% -33.3%
Cash From Investing Activities $444.0K $27.66M
YoY Change -99.12% -33.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -167.0K -187.9M
YoY Change -101.5% -445.93%
NET CHANGE
Cash From Operating Activities -62.02M 59.73M
Cash From Investing Activities 444.0K 27.66M
Cash From Financing Activities -167.0K -187.9M
Net Change In Cash -61.74M -100.5M
YoY Change -945.74% -277.08%
FREE CASH FLOW
Cash From Operating Activities -$62.02M $59.73M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-272000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-248000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1489546000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1579500000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-84108000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-193425000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
674855000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
629604000
CY2024Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
64979000
CY2023Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
58716000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
142042000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
91152000
CY2024Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
28368000
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
24848000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
62954000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
41722000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21955000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23267000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
50425000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
57421000
CY2024Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
35165000
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
45144000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
91697000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
94297000
CY2024Q2 us-gaap Costs And Expenses
CostsAndExpenses
85488000
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
93259000
us-gaap Costs And Expenses
CostsAndExpenses
205076000
us-gaap Costs And Expenses
CostsAndExpenses
193440000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-20509000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-34543000
us-gaap Operating Income Loss
OperatingIncomeLoss
-63034000
us-gaap Operating Income Loss
OperatingIncomeLoss
-102288000
CY2024Q2 us-gaap Interest Expense
InterestExpense
5334000
CY2023Q2 us-gaap Interest Expense
InterestExpense
9943000
us-gaap Interest Expense
InterestExpense
16450000
us-gaap Interest Expense
InterestExpense
19655000
CY2024Q2 us-gaap Gain Loss On Sale Of Interest In Projects
GainLossOnSaleOfInterestInProjects
24085000
us-gaap Gain Loss On Sale Of Interest In Projects
GainLossOnSaleOfInterestInProjects
177732000
CY2024Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-12630000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-12630000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1467000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1617000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4336000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3345000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12921000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-42869000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
89954000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-118598000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-12921000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-42869000
us-gaap Net Income Loss
NetIncomeLoss
89954000
us-gaap Net Income Loss
NetIncomeLoss
-118598000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.79
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.42
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.73
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.42
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
114819965
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
87269614
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
113784636
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
83469247
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
114819965
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
87269614
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
126174802
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
83469247
CY2024Q2 us-gaap Profit Loss
ProfitLoss
-12921000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-42869000
us-gaap Profit Loss
ProfitLoss
89954000
us-gaap Profit Loss
ProfitLoss
-118598000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-18000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-24000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-47000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-12921000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-42888000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
89930000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-118646000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-193425000
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001512762
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
112215260
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
115198655
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36721
dei Entity Registrant Name
EntityRegistrantName
Coherus BioSciences, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-3615821
dei Entity Address Address Line1
EntityAddressAddressLine1
333 Twin Dolphin Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 600
dei Entity Address City Or Town
EntityAddressCityOrTown
Redwood City
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94065
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
649-3530
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
CHRS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
115208583
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
159240000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
102891000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
14857000
CY2024Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
175251000
CY2023Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
260522000
CY2024Q2 chrs Transition Services Agreement Receivable Current
TransitionServicesAgreementReceivableCurrent
138317000
CY2024Q2 us-gaap Inventory Net
InventoryNet
62162000
CY2023Q4 us-gaap Inventory Net
InventoryNet
62605000
CY2024Q2 chrs Prepaid Manufacturing Expense Current
PrepaidManufacturingExpenseCurrent
9179000
CY2023Q4 chrs Prepaid Manufacturing Expense Current
PrepaidManufacturingExpenseCurrent
23657000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
13782000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11099000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
557931000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
475631000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3334000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5119000
CY2024Q2 us-gaap Inventory Noncurrent
InventoryNoncurrent
49879000
CY2023Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
67495000
CY2024Q2 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
55455000
CY2023Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
71673000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
8256000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
9686000
CY2024Q2 us-gaap Assets
Assets
674855000
CY2023Q4 us-gaap Assets
Assets
629604000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
76818000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
35219000
CY2024Q2 chrs Accrued Rebates Fees And Reserve Current
AccruedRebatesFeesAndReserveCurrent
177455000
CY2023Q4 chrs Accrued Rebates Fees And Reserve Current
AccruedRebatesFeesAndReserveCurrent
169645000
CY2024Q2 chrs Transition Services Agreement Payables And Other Accrued Liabilities Current
TransitionServicesAgreementPayablesAndOtherAccruedLiabilitiesCurrent
133536000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
14152000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
21521000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
61044000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
105386000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
463005000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
331771000
CY2024Q2 chrs Term Loans Payable Noncurrent
TermLoansPayableNoncurrent
36541000
CY2023Q4 chrs Term Loans Payable Noncurrent
TermLoansPayableNoncurrent
246481000
CY2024Q2 us-gaap Convertible Subordinated Debt Noncurrent
ConvertibleSubordinatedDebtNoncurrent
227555000
CY2023Q4 us-gaap Convertible Subordinated Debt Noncurrent
ConvertibleSubordinatedDebtNoncurrent
226888000
CY2024Q2 chrs Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
4165000
CY2023Q4 chrs Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
5328000
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
27697000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
12561000
CY2024Q2 us-gaap Liabilities
Liabilities
758963000
CY2023Q4 us-gaap Liabilities
Liabilities
823029000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
115198655
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
112215260
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
12000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
11000
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1405698000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1386312000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
102875000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
291000
CY2024Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
745000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7677000
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-24000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-81844000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-12921000
CY2024Q2 chrs Stock Issued During Period Partial Payout Bonus
StockIssuedDuringPeriodPartialPayoutBonus
4408000
CY2024Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1711000
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
685000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7327000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-84108000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-137418000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-75729000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
103000
CY2023Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
2781000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12288000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-29000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-196507000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-42869000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
14000
CY2023Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
305000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1337000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10034000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-19000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-174764000
us-gaap Profit Loss
ProfitLoss
89954000
us-gaap Profit Loss
ProfitLoss
-118598000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2694000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1829000
us-gaap Share Based Compensation
ShareBasedCompensation
14550000
us-gaap Share Based Compensation
ShareBasedCompensation
22359000
chrs Impairment Of Intangible Assets And Contingent Value Rights Liability
ImpairmentOfIntangibleAssetsAndContingentValueRightsLiability
6772000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-12630000
us-gaap Gain Loss On Sale Of Interest In Projects
GainLossOnSaleOfInterestInProjects
177732000
us-gaap Inventory Write Down
InventoryWriteDown
2481000
us-gaap Inventory Write Down
InventoryWriteDown
2894000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-1267000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-556000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-85217000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
31350000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
18557000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
15715000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-7170000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-302000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4249000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-4785000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
40077000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
17786000
chrs Increase Decrease In Accrued Rebates Fees And Reserve
IncreaseDecreaseInAccruedRebatesFeesAndReserve
6523000
chrs Increase Decrease In Accrued Rebates Fees And Reserve
IncreaseDecreaseInAccruedRebatesFeesAndReserve
26383000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
4781000
chrs Increase Decrease In Accrued Compensation
IncreaseDecreaseInAccruedCompensation
-2643000
chrs Increase Decrease In Accrued Compensation
IncreaseDecreaseInAccruedCompensation
-8472000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-45871000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-9294000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
12968000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-107647000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
6200000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
64750000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
8688000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
13282000
chrs Payments For Milestone Based License Fee
PaymentsForMilestoneBasedLicenseFee
12500000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
19507000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-208000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-366000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
230419000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
58891000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
37120000
chrs Proceeds From Revenue Purchase And Sale Agreement Net
ProceedsFromRevenuePurchaseAndSaleAgreementNet
36495000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
291000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
117000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
685000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1337000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2456000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
3086000
us-gaap Repayments Of Debt
RepaymentsOfDebt
260387000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-241000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-625000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-187038000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
58129000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
56349000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9373000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
103343000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
63987000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
159692000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
73360000
us-gaap Stock Issued1
StockIssued1
4408000
chrs Issuance Cost Of Debt Incurred But Not Yet Paid
IssuanceCostOfDebtIncurredButNotYetPaid
1008000
CY2024Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-12600000
CY2024Q2 chrs Product Pipeline Number Of Drug Candidates
ProductPipelineNumberOfDrugCandidates
3
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information. Accounting estimates and judgments are inherently uncertain and therefore actual results could differ from these estimates.</p>
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
102891000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
63547000
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
452000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
440000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
103343000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
63987000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
159240000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
72920000
CY2024Q2 us-gaap Restricted Cash
RestrictedCash
452000
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
440000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
159692000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
73360000
CY2024Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
64979000
CY2023Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
58716000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
142042000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
91152000
CY2024Q2 chrs Provision Related To Sales Made In Prior Period
ProvisionRelatedToSalesMadeInPriorPeriod
2800000
CY2023Q2 chrs Provision Related To Sales Made In Prior Period
ProvisionRelatedToSalesMadeInPriorPeriod
3100000
CY2023Q4 chrs Reserve For Discounts And Allowances Constitute Variable Consideration
ReserveForDiscountsAndAllowancesConstituteVariableConsideration
244885000
chrs Reserve For Sales Discounts And Allowances Constitute Variable Consideration
ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration
676006000
chrs Provision Related To Sales Made In Prior Period
ProvisionRelatedToSalesMadeInPriorPeriod
4066000
chrs Payments And Customer Credits Issued From Reserve For Discounts And Allowances Constitute Variable Consideration
PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration
673859000
CY2024Q2 chrs Reserve For Discounts And Allowances Constitute Variable Consideration
ReserveForDiscountsAndAllowancesConstituteVariableConsideration
251098000
CY2022Q4 chrs Reserve For Discounts And Allowances Constitute Variable Consideration
ReserveForDiscountsAndAllowancesConstituteVariableConsideration
100503000
chrs Reserve For Sales Discounts And Allowances Constitute Variable Consideration
ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration
309019000
chrs Provision Related To Sales Made In Prior Period
ProvisionRelatedToSalesMadeInPriorPeriod
3509000
chrs Payments And Customer Credits Issued From Reserve For Discounts And Allowances Constitute Variable Consideration
PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration
278464000
CY2023Q2 chrs Reserve For Discounts And Allowances Constitute Variable Consideration
ReserveForDiscountsAndAllowancesConstituteVariableConsideration
134567000
CY2024Q2 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
9200000
CY2024Q2 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
9200000
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
145814000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
145814000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
104324000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
11000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
104315000
CY2024Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
12192000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
12975000
CY2024Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
89090000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
82588000
CY2024Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
10759000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
34537000
CY2024Q2 us-gaap Inventory Gross
InventoryGross
112041000
CY2023Q4 us-gaap Inventory Gross
InventoryGross
130100000
CY2024Q2 us-gaap Inventory Net
InventoryNet
62162000
CY2023Q4 us-gaap Inventory Net
InventoryNet
62605000
CY2024Q2 us-gaap Inventory Noncurrent
InventoryNoncurrent
49879000
CY2023Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
67495000
CY2024Q2 chrs Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
112041000
CY2023Q4 chrs Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
130100000
CY2024Q2 chrs Prepaid Manufacturing Expense Current
PrepaidManufacturingExpenseCurrent
9200000
CY2024Q2 chrs Prepayments Made To Cmo For Manufacturing Services
PrepaymentsMadeToCmoForManufacturingServices
6100000
CY2024Q2 chrs Prepayments Made To Cmo For Other Research And Development Pipeline Program
PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram
3100000
CY2023Q4 chrs Prepaid Manufacturing Expense Current
PrepaidManufacturingExpenseCurrent
23700000
CY2023Q4 chrs Prepayments Made To Cmo For Other Research And Development Pipeline Program
PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram
11100000
CY2023Q4 chrs Prepayments Made To Cmo For Manufacturing Services
PrepaymentsMadeToCmoForManufacturingServices
12600000
CY2024Q2 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
23653000
CY2023Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
25770000
CY2024Q2 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
20319000
CY2023Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
20651000
CY2024Q2 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
3334000
CY2023Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
5119000
CY2024Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
500000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1100000
CY2023Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
800000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1700000
CY2024Q2 us-gaap Capitalized Computer Software Net
CapitalizedComputerSoftwareNet
2600000
CY2023Q4 us-gaap Capitalized Computer Software Net
CapitalizedComputerSoftwareNet
3200000
CY2024Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1411000
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
639000
CY2024Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
26596000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
41871000
CY2024Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
28859000
CY2023Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
28859000
CY2023Q4 us-gaap Goodwill
Goodwill
943000
CY2024Q2 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
55455000
CY2023Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
71673000
CY2024Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
700000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1600000
chrs Finite Lived Intangible Asset Expected Amortization For Each Of Five Succeeding Fiscal Years
FiniteLivedIntangibleAssetExpectedAmortizationForEachOfFiveSucceedingFiscalYears
2700000
CY2024Q2 chrs Accrued Commercial And Research And Development Manufacturing Liabilities Current
AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent
17055000
CY2023Q4 chrs Accrued Commercial And Research And Development Manufacturing Liabilities Current
AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent
23470000
CY2024Q2 chrs Accrued Co Development Costs And Milestone Payments
AccruedCoDevelopmentCostsAndMilestonePayments
12500000
CY2023Q4 chrs Accrued Co Development Costs And Milestone Payments
AccruedCoDevelopmentCostsAndMilestonePayments
26812000
CY2024Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
3583000
CY2023Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
42031000
CY2024Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
9202000
CY2024Q2 chrs Royalty Participation Liability Current
RoyaltyParticipationLiabilityCurrent
2682000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
14586000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
7628000
CY2024Q2 chrs Lease Liabilities Operating And Financing
LeaseLiabilitiesOperatingAndFinancing
1436000
CY2023Q4 chrs Lease Liabilities Operating And Financing
LeaseLiabilitiesOperatingAndFinancing
2145000
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
3300000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
61044000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
105386000
CY2024Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
632000
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
1172000
CY2024Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1102000
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1102000
CY2024Q2 chrs Royalty Participation Liability Noncurrent
RoyaltyParticipationLiabilityNoncurrent
25963000
CY2023Q4 us-gaap Other Sundry Liabilities Noncurrent
OtherSundryLiabilitiesNoncurrent
10287000
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
27697000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
12561000
CY2022Q1 chrs Collaboration Agreement Option Exercise Fee Per Program
CollaborationAgreementOptionExerciseFeePerProgram
35000000.0
CY2024Q1 chrs Milestone Payments Amount Per Each Installment
MilestonePaymentsAmountPerEachInstallment
12500000
CY2023Q4 us-gaap Accrued Royalties Current And Noncurrent
AccruedRoyaltiesCurrentAndNoncurrent
38400000
CY2024Q1 us-gaap Disposal Group Including Discontinued Operation Consideration
DisposalGroupIncludingDiscontinuedOperationConsideration
170000000.0
CY2024Q1 chrs Disposal Group Including Discontinued Operation Additional Consideration For Product Inventory And Prepaid Manufacturing Assets
DisposalGroupIncludingDiscontinuedOperationAdditionalConsiderationForProductInventoryAndPrepaidManufacturingAssets
17800000
us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.133
CY2024Q1 chrs Debt Partial Prepayment To Be Made
DebtPartialPrepaymentToBeMade
175000000.0
CY2024Q1 chrs Minimum Net Sales Convenant Level Agreed To Be Maintained Over Past Year
MinimumNetSalesConvenantLevelAgreedToBeMaintainedOverPastYear
125000000.0
CY2020Q2 us-gaap Share Price
SharePrice
14.82
CY2024Q2 us-gaap Share Price
SharePrice
1.73
CY2024Q2 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
12715000
CY2024Q2 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
39681000
CY2024Q2 us-gaap Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
860000
CY2024Q2 us-gaap Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
300000
CY2024Q2 us-gaap Purchase Obligation
PurchaseObligation
53556000
CY2024Q2 us-gaap Business Combination Liabilities Arising From Contingencies Amount Recognized
BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized
17000000.0
CY2022Q2 us-gaap Product Liability Contingency Loss Exposure Not Accrued Best Estimate
ProductLiabilityContingencyLossExposureNotAccruedBestEstimate
14000000.0
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7231000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10077000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14550000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22359000
CY2024Q2 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
400000
CY2023Q2 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
193000
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
794000
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
324000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-12921000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-42869000
us-gaap Net Income Loss
NetIncomeLoss
89954000
us-gaap Net Income Loss
NetIncomeLoss
-118598000
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
114819965
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
87269614
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
113784636
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
83469247
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.79
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.42
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-12921000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-42869000
us-gaap Net Income Loss
NetIncomeLoss
89954000
us-gaap Net Income Loss
NetIncomeLoss
-118598000
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
2392000
CY2024Q2 us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
-12921000
CY2023Q2 us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
-42869000
us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
92346000
us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
-118598000
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
114819965
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
87269614
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
113784636
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
83469247
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
231846
us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
216168
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
11942152
CY2024Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
114819965
CY2023Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
87269614
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
126174802
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
83469247
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.73
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.42
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
40933658
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
37593041
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
28083612
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
38118321
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-011629-index-headers.html Edgar Link pending
0001558370-24-011629-index.html Edgar Link pending
0001558370-24-011629.txt Edgar Link pending
0001558370-24-011629-xbrl.zip Edgar Link pending
chrs-20240630.xsd Edgar Link pending
chrs-20240630x10q.htm Edgar Link pending
chrs-20240630xex10d3.htm Edgar Link pending
chrs-20240630xex10d4.htm Edgar Link pending
chrs-20240630xex10d5.htm Edgar Link pending
chrs-20240630xex31d1.htm Edgar Link pending
chrs-20240630xex31d2.htm Edgar Link pending
chrs-20240630xex32d1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
chrs-20240630_cal.xml Edgar Link unprocessable
chrs-20240630_def.xml Edgar Link unprocessable
chrs-20240630_lab.xml Edgar Link unprocessable
chrs-20240630x10q_htm.xml Edgar Link completed
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
chrs-20240630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable